person
as of 2026-07-01Jonathan M. Meyer, MD
Jonathan M Meyer, MD
ORCID 0000-0001-7294-4834
at a glance
Roles: Principal Investigator, Author
KOL signal score 8
5 publications · 0 high-value
Cross-drug reach: 3 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
University of California, San Diego
Roles
Principal Investigator, Author
KOL signal
8
Publications
5 (0 high-value)
Trial investigator
no
Publishes on
3 drugs
Trials led
2
Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00167817Phase 4Completed
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes
NCT00338949Phase 4Completed
Publications & congress
3
Xanomeline-Trospium for the Treatment of Schizophrenia.
Focus (American Psychiatric Publishing) · 2025
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trials.
The international journal of neuropsychopharmacology · 2025
How antipsychotics work in schizophrenia: a primer on mechanisms.
CNS spectrums · 2024
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on